Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder

Journal of Autism and Developmental Disorders

Volumn 44, Issue 4, 2014, Pages 981-987

  Erickson, Craig A ^a,b,c   Wink, Logan K ^a,b,c   Early, Maureen C ^a,b   Stiegelmeyer, Elizabeth ^a,b   Mathieu Frasier, Lauren ^a,b,c   Patrick, Vanessa ^a,b   McDougle, Christopher J ^a,b,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acamprosate; Autism spectrum disorder; Gamma aminobutyric acid; Glutamate

Indexed keywords

ACAMPROSATE; AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; CLONIDINE; DEXMETHYLPHENIDATE; FLUOXETINE; GUANFACINE; METHYLPHENIDATE; MIRTAZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; SERTRALINE; TRAZODONE; VALPROIC ACID;

ABERRANT BEHAVIOR CHECKLIST SOCIAL WITHDRAWAL SUBSCALE; ADOLESCENT; ARTICLE; AUTISM; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERACTIVITY; INSOMNIA; INTELLIGENCE QUOTIENT; IRRITABILITY; LOOSE FECES; MALE; NEUROTRANSMISSION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SOCIAL BEHAVIOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PILOT PROJECTS; SINGLE-BLIND METHOD; SOCIAL BEHAVIOR; TAURINE; TREATMENT OUTCOME;

EID: 84896373801     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-013-1943-3     Document Type: Article

References (34)

1. Aman, M. G.; Singh, N. N.; Stewart, A. W.; Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485-491. (Pubitemid 15104762)
2. Bear, M. F. (2005). Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes, Brain and Behavior, 4(6), 393-398. doi: 10.1111/j.1601-183X.2005.00135.x. (Pubitemid 41192450)
3. Bear, M. F.; Huber, K. M.; Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7), 370-377. doi: 10.1016/j.tins.2004.04.009. (Pubitemid 38829251)
4. Blednov, Y. A.; Adron Harris, R. (2008). Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: Relationship to acamprosate actions. International Journal of Neuropsychopharmacology, 11(6), 775-793. doi: 10.1017/S1461145708008584.
5. ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 25 October 2012.
6. Constantino, J. N.; Davis, S. A.; Todd, R. D.; Schindler, M. K.; Gross, M. M.; Brophy, S. L.; et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33(4), 427-433. (Pubitemid 37127938)
7. D'Hulst, C.; De Geest, N.; Reeve, S. P.; Van Dam, D.; De Deyn, P. P.; Hassan, B. A.; et al. (2006). Decreased expression of the GABAA receptor in fragile X syndrome. Brain Research, 1121(1), 238-245. doi: 10.1016/j.brainres. 2006.08.115. (Pubitemid 44708899)
8. D'Hulst, C.; Kooy, R. F. (2007). The GABAA receptor: A novel target for treatment of fragile X? Trends in Neurosciences, 30(8), 425-431. doi: 10.1016/j.tins.2007.06.003. (Pubitemid 47088715)
9. Erickson, C. A.; Early, M.; Stigler, K. A.; Wink, L. K.; Mullett, J. E.; McDougle, C. J. (2011). An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. [Clinical Trial Research Support, N.I.H.; Extramural Research Support, Non-U.S. Gov't]. Journal of Child and Adolescent Psychopharmacology, 21(6), 565-569. doi: 10.1089/cap.2011.0034.
10. Erickson, C. A.; Mullett, J. E.; McDougle, C. J. (2010). Brief report: Acamprosate in fragile X syndrome. [Case Reports Research Support, N.I.H.; Extramural Research Support, Non-U.S. Gov't]. Journal of Autism and Developmental Disorders, 40(11), 1412-1416. doi: 10.1007/s10803-010-0988-9.
11. Erickson, C. A.; Wink, L. K.; Ray, B.; Early, M. C.; Stiegelmeyer, E.; Mathieu-Frasier, L.; et al. (2013). Impact of acamprosate on behavior and brain-derived neurotrophic factor: An open-label study in youth with fragile X syndrome. Psychopharmacology (Berl),. doi: 10.1007/s00213-013-3022-z.
12. Gupta, T.; Syed, Y. M.; Revis, A. A.; Miller, S. A.; Martinez, M.; Cohn, K. A.; et al. (2008). Acute effects of acamprosate and MPEP on ethanol drinking-in-the-dark in male C57BL/6 J mice. Alcoholism: Clinical and Experimental Research, 32(11), 1992-1998. doi: 10.1111/j.1530-0277.2008.00787.x.
13. Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76-338. Washington, DC: U.S. DHEW, NIMH.
14. Harris, B. R.; Prendergast, M. A.; Gibson, D. A.; Rogers, D. T.; Blanchard, J. A.; Holley, R. C.; et al. (2002). Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcoholism: Clinical and Experimental Research, 26(12), 1779-1793. doi: 10.1097/01.ALC.0000042011.99580.98. (Pubitemid 36008614)
15. King, B. H.; Hollander, E.; Sikich, L.; McCracken, J. T.; Scahill, L.; Bregman, J. D.; et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583-590. doi: 10.1001/archgenpsychiatry.2009.30.
16. Kotlinska, J.; Bochenski, M. (2008). The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. European Journal of Pharmacology, 598(1-3), 57-63. doi: 10.1016/j.ejphar.2008.09.026.
17. Lindemann, L.; Jaeschke, G.; Michalon, A.; Vieira, E.; Honer, M.; Spooren, W.; et al. (2011). CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. [Research Support, Non-U.S. Gov't]. Journal of Pharmacology and Experimental Therapeutics, 339(2), 474-486. doi: 10.1124/jpet.111.185660.
18. Lord, C.; Rutter, M.; Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659-685. (Pubitemid 24309810)
19. Mann, K.; Kiefer, F.; Spanagel, R.; Littleton, J. (2008). Acamprosate: Recent findings and future research directions. Alcoholism: Clinical and Experimental Research, 32(7), 1105-1110. doi: 10.1111/j.1530-0277.2008.00690.x.
20. Marcus, R. N.; Owen, R.; Kamen, L.; Manos, G.; McQuade, R. D.; Carson, W. H.; et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110-1119. doi: 10.1097/CHI.0b013e3181b76658.
21. Mayer, S.; Harris, B.; Gibson, D. A.; Blanchard, J.; Prendergast, M. A.; Holley, R. C.; et al. (2002). Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcoholism: Clinical and Experimental Research, 26(5), 655-662. (Pubitemid 34522672)
22. McCracken, J. T.; McGough, J.; Shah, B.; Cronin, P.; Hong, D.; Aman, M. G.; et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314-321. (Pubitemid 34815353)
23. McDougle, C. J.; Erickson, C. A.; Stigler, K. A.; Posey, D. J. (2005). Neurochemistry in the pathophysiology of autism. Journal of Clinical Psychiatry, 66(Suppl 10), 9-18. (Pubitemid 43133209)
24. Naassila, M.; Hammoumi, S.; Legrand, E.; Durbin, P.; Daoust, M. (1998). Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcoholism: Clinical and Experimental Research, 22(4), 802-809. (Pubitemid 28292462)
25. Pierrefiche, O.; Daoust, M.; Naassila, M. (2004). Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology, 47(1), 35-45. doi: 10.1016/j.neuropharm.2004.03.004. (Pubitemid 38686309)
26. Posey, D. J.; Erickson, C. A.; McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child and adolescent psychiatric clinics of North America, 17(4), 787-801, viii-ix. doi: 10.1016/j.chc.2008.06.010.
27. Reilly, M. T.; Lobo, I. A.; McCracken, L. M.; Borghese, C. M.; Gong, D.; Horishita, T.; et al. (2008). Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcoholism: Clinical and Experimental Research, 32(2), 188-196. doi: 10.1111/j.1530-0277.2007.00569.x.
28. Research Units on Pediatric Psychopharmacology Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266-1274. doi: 10.1001/archpsyc.62.11.1266. (Pubitemid 41586926)
29. Scahill, L.; Hallett, V.; Aman, M. G.; McDougle, C. J.; Eugene Arnold, L.; McCracken, J. T.; et al. (2013). Brief report: Social disability in autism spectrum disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders, 43(3), 739-746. doi: 10.1007/s10803-012-1689-3.
30. Scahill, L.; McDougle, C. J.; Williams, S. K.; Dimitropoulos, A.; Aman, M. G.; McCracken, J. T.; et al. (2006). Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45(9), 1114-1123. (Pubitemid 44343067)
31. Silverman, J. L.; Tolu, S. S.; Barkan, C. L.; Crawley, J. N. (2010). Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. [Research Support, N.I.H.; Intramural]. Neuropsychopharmacology, 35(4), 976-989. doi: 10.1038/npp.2009.201.
32. Yan, Q. J.; Rammal, M.; Tranfaglia, M.; Bauchwitz, R. P. (2005). Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. [Research Support, Non-U.S. Gov't]. Neuropharmacology, 49(7), 1053-1066. doi: 10.1016/j.neuropharm.2005.06.004. (Pubitemid 41503304)
33. Yizhar, O.; Fenno, L. E.; Prigge, M.; Schneider, F.; Davidson, T. J.; O'Shea, D. J.; et al. (2011). Neocortical excitation/inhibition balance in information processing and social dysfunction [Research Support, N.I.H.; Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. Nature, 477(7363), 171-178. doi: 10.1038/nature10360.
34. Zhang, S.; Faries, D. E.; Vowles, M.; Michelson, D. (2005). ADHD rating scale IV: Psychometric properties from a multinational study as a clinician-administered instrument. International Journal of Methods in Psychiatric Research, 14(4), 186-201. (Pubitemid 43013586)